Prelude Capital Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Prelude Capital Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-900	Closed	-$3K	–	2051
2017 Q3	$3K	Buy	+900	New	+$3.01K	﹤0.01%	1551
2017 Q2	–	Sell	-23,400	Closed	-$98K	–	2131
2017 Q1	$98K	Buy	23,400 +22,100	+1,700%	+$102K	0.01%	791
2016 Q4	$5K	Sell	1,300 -1,190	-48%	-$4.94K	﹤0.01%	1445
2016 Q3	$9K	Buy	2,490 +1,910	+329%	+$6.95K	﹤0.01%	1450
2016 Q2	$2K	Buy	+580	New	+$2.66K	﹤0.01%	1523
2015 Q4	–	Sell	-2,850	Closed	-$42K	–	1974
2015 Q3	$42K	Sell	2,850 -5,000	-64%	-$86.4K	0.01%	1104
2015 Q2	$153K	Buy	+7,850	New	+$152K	0.02%	737

Other funds holding CTIC

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sphera Funds Management Tel Aviv, Israel $581M AUM 108.65% 1-Year Est. Return

Renaissance Technologies

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return